By T N Ashok
NEW YORK: India’s pharma heavyweight Dr. Reddy’s Laboratories (NSE: REDY) , based out of the Southern city of Hyderabad, announced its audacious plan to launch a generic version of Novo Nordisk’s wildly successful weight-loss drug Wegovy in 87 countries next year, joining the global gold rush in the $150-billion obesity drug market. The drug is expected to have a big market in USA despite Trump’s threat of imposing high tariffs on Indian pharma products.
The Indian company plans to be disruptor with aggressive pricing at $100 a month for low income groups accessibility against western pharma’s high cost $1,000 per month pricing in the west. The move, revealed by CEO Erez Israeli during the company’s earnings press conference on Wednesday, positions Dr. Reddy’s at the front line of an emerging generics battle over semaglutide, the active ingredient in both Wegovy and its diabetes cousin Ozempic.
With patent expirations looming in key territories and regulatory filings already in motion, Dr. Reddy’s is betting that its low-cost model, global distribution muscle, and decades of experience challenging pharmaceutical monopolies can unlock billions in new revenue — even as lawsuits and geopolitical scrutiny hover.
Semaglutide-based drugs, specifically Wegovy by Denmark’s Novo Nordisk and Mounjaro by U.S. giant Eli Lilly, have seen skyrocketing demand in recent years for their effectiveness in managing both obesity and type 2 diabetes. These GLP-1 receptor agonists not only regulate insulin and blood sugar but also suppress appetite — a pharmaceutical one-two punch that has upended traditional approaches to weight management.
The global market for obesity medications is projected to balloon to $150 billion by the early 2030s, and generic manufacturers are racing to grab a slice. But the first movers are often the ones with the strongest international reach — and this is where Indian pharma shines.
Export figures from India’s Ministry of Commerce show that over $25 billion worth of pharmaceutical products were exported in FY 2024, with the United States alone accounting for over $8 billion — making it India’s single largest export destination. The European Union ranks second.
Leading players in this global ecosystem include Sun Pharma, Cipla, Lupin, Aurobindo Pharma, Biocon, and Dr. Reddy’s Laboratories. These companies have historically relied on the Hatch-Waxman Act in the U.S. to launch ANDA (Abbreviated New Drug Applications) and Paragraph IV challenges against big-brand patents, successfully disrupting entrenched monopolies.
Founded in 1984 and headquartered in Hyderabad, Dr. Reddy’s Laboratories has a long and combative history with big pharma over generic rights. From fluoxetine (generic Prozac) in the 2000s to fondaparinux (generic Arixtra) and more recently biosimilars of blockbuster oncology drugs, Reddy’s has taken pride in being an early challenger.
In the past, this aggressive approach has brought scrutiny. In 2015, the U.S. FDA issued a warning letter over manufacturing violations at one of Reddy’s key facilities. In 2020, the company voluntarily recalled multiple batches of ranitidine (generic Zantac) after impurities linked to cancer risk were detected. Reddy’s has also faced litigation for alleged patent infringement, including on buprenorphine-naloxone (used to treat opioid addiction), which led to temporary injunctions in U.S. courts.
The latest controversy is no different. In May 2025, Novo Nordisk sued Dr. Reddy’s, accusing the company of infringing patents related to semaglutide. While Reddy’s has not commented on pending litigation, Israeli confirmed that regulatory filings have already been made in all 87 target countries, including India, Brazil, Canada, Turkey, and several Southeast Asian and African nations.
“The U.S. and European markets will open between 2029 and 2033,” Israeli said, referencing expected patent expirations in Western markets. But emerging economies, where patent protections are weaker or expiring sooner — India’s semaglutide patent, for instance, lapses in March 2026 — will likely see generics much earlier.
Indian drugmakers have also come under increasing regulatory and trade pressure from Western governments. In the United States, bipartisan calls to scrutinize drug imports — often couched in national security language — have led to tariff threats and stricter FDA inspections of Indian facilities. Washington’s recent “Buy American” push in healthcare procurement has also impacted the predictability of exports.
Reddy’s, like its peers, has lobbied U.S. regulators to ensure that India’s FDA-approved facilities are not treated differently from U.S.-based plants, a battle that is far from over. Still, the economics or the optics are hard to ignore. A generic version of Wegovy could cost a fraction — potentially under $100 per month, compared to $1,000+ retail prices in the U.S. — making it transformative for developing nations and attractive to cost-conscious Western buyers once patents lapse.
Israeli said Dr. Reddy’s is not stopping at semaglutide. The company plans to launch 26 GLP-1-based products over the next 10 years, covering both injectables and oral formulations. That includes biosimilars, combination therapies, and long-acting formulations.“We’re not just making a cheaper drug,” Israeli said. “We’re building a long-term, globally accessible obesity and metabolic disease portfolio.”With nearly one billion overweight or obese individuals globally and spiralling rates of type 2 diabetes, the demand is overwhelming.
Reddy’s is far from alone. Fellow Indian giants Cipla, Lupin, Sun Pharma, and Biocon have all declared intentions to enter the obesity-drug space. Cipla, already expanding its inhalation and peptide manufacturing units, is rumored to be in talks for licensing deals on GLP-1 agonist analogues. Biocon, with its insulin biosimilar success, is eyeing the combination diabetes-obesity drug class.
Novo Nordisk and Eli Lilly, meanwhile, are scrambling to protect their turf — ramping up marketing, patent extensions, and legal muscle to slow the generics wave. Novo has already launched Wegovy in India, racing against the clock before generics hit shelves.
Dr. Reddy’s generics push comes at a high-stakes moment for global pharma: rising prices in Western markets, exploding demand in emerging economies, and growing political scrutiny of drug supply chains. The company’s aggressive bet on semaglutide generics positions it to potentially rake in hundreds of millions in new revenue over the next five years — if it can navigate litigation, patent minefields, regulatory gauntlets, and geopolitical headwinds. (IPA Service)
Jagdeep Dhankar’s Parting Has Lessons For Narendra Modi And BJP Leadership 